Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Gains from Sales and Divestitures (2017 - 2024)

Historic Gains from Sales and Divestitures for UroGen Pharma (URGN) over the last 8 years, with Q4 2024 value amounting to $385065.0.

  • UroGen Pharma's Gains from Sales and Divestitures rose 3114.13% to $385065.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $385065.0, marking a year-over-year increase of 3114.13%. This contributed to the annual value of $385065.0 for FY2024, which is 3114.13% up from last year.
  • UroGen Pharma's Gains from Sales and Divestitures amounted to $385065.0 in Q4 2024, which was up 3114.13% from $293626.0 recorded in Q4 2023.
  • In the past 5 years, UroGen Pharma's Gains from Sales and Divestitures ranged from a high of $385065.0 in Q4 2024 and a low of $85954.0 during Q4 2020
  • For the 5-year period, UroGen Pharma's Gains from Sales and Divestitures averaged around $284417.0, with its median value being $293626.0 (2023).
  • As far as peak fluctuations go, UroGen Pharma's Gains from Sales and Divestitures plummeted by 5327.95% in 2020, and later skyrocketed by 22941.69% in 2021.
  • Over the past 5 years, UroGen Pharma's Gains from Sales and Divestitures (Quarter) stood at $85954.0 in 2020, then soared by 229.42% to $283147.0 in 2021, then soared by 32.19% to $374293.0 in 2022, then fell by 21.55% to $293626.0 in 2023, then skyrocketed by 31.14% to $385065.0 in 2024.
  • Its last three reported values are $385065.0 in Q4 2024, $293626.0 for Q4 2023, and $374293.0 during Q4 2022.